Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial

Cardiovascular Intervention and Therapeutics - 2021
Hirotoshi Watanabe1, Takenori Domei, Takeshi Morimoto2, Masahiro Natsuaki3, Hiroki Shiomi4, Toshiaki Takahashi1, Masanobu Ohya5, Satoru Suwa6, Kensuke Takagi7, Mamoru Nanasato8, Yutaka Hata9, Minoru Yagi10, Nobuhiro Suematsu11, Takafumi Yokomatsu12, Itaru Takamisawa13, Masayuki Doi9, Toshiyuki Noda14, Hideki Okayama15, Yoshitane Seino16, Takeshi Tada17, Hiroki Sakamoto18, Kiyoshi Hibi18, Mitsuru Abe19, Kensuke Kawai20, Kōichi Nakao21, Kenji Ando22, Kengo Tanabe2, Yuji Ikari23, Keiichi Igarashi Hanaoka24, Yoshihiro Morino25, Ken Kozuma26, Kazushige Kadota27, Yutaka Furukawa6, Yoshihisa Nakagawa5, Takeshi Kimura28, Stopdapt Investigators1
1Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
2Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan
3Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan
4Department of Cardiovascular Medicine, Saga University, Saga, Japan
5Department of Cardiovascular Medicine, Kobe City Medical Center General Hospital, Kobe, Japan
6Department of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan
7Department of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni, Japan
8Department of Cardiology, Ogaki Municipal Hospital, Ogaki, Japan
9Department of Cardiology, Sakakibara Heart Institute, Fuchu, Japan
10Department of Cardiology, Minamino Cardiovascular Hospital, Hachioji, Japan
11Department of cardiology, Sendai Cardiovascular Center, Sendai, Japan
12Department of Cardiology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
13Department of Cardiology, Mitsubishi Kyoto Hospital, Kyoto, Japan
14Department of Cardiology, Kagawa Prefectural Central Hospital, Takamatsu, Japan.
15Department of Cardiology, Gifu Prefectural General Medical Center, Gifu, Japan
16Department of Cardiology, Ehime Prefectural Central Hospital, Matsuyama, Japan
17Department of Cardiology, Hoshi General Hospital, Koriyama, Japan
18Department of Cardiology, Shizuoka General Hospital, Shizuoka, Japan
19Division of Cardiology, Yokohama City University Medical Center, Yokohama, Japan
20Department of Cardiology, National Hospital Organization Kyoto Medical Center, Kyoto, Japan
21Department of Cardiology, Chikamori Hospital, Kochi, Japan
22Division of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan
23Division of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan
24Department of Cardiology, Tokai University Hospital, Isehara, Japan
25Hanaoka Seishu Memorial Cardiovascular Clinic, Sapporo, Japan
26Department of Cardiology, Iwate Medical University Hospital, Morioka, Japan
27Department of Cardiology, Teikyo University Hospital, Tokyo, Japan
28Department of Cardiovascular Medicine, Shiga University of Medical Science, Otsu, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the. Circulation. 2016;134:e123–55.

Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European. Eur Heart J. 2018;39:213–60.

Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrié D, Naber C, et al. Polymer-free drug-coated coronary stents in patients at high bleeding risk. N Engl J Med. 2015;373:2038–47.

Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805–15.

Varenne O, Cook S, Sideris G, Kedev S, Cuisset T, Carrié D, et al. Drug-eluting stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial. Lancet. 2018;391(10115):41–50.

Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321:2414–27.

Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, et al. Defining high bleeding risk in patients undergoing percutaneous coronary intervention. Circulation. 2019;140:240–61.

Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, et al. Very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial. Circulation. 2019. https://doi.org/10.1161/circulationaha.119.043613.

Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents risk scores from Paris. J Am Coll Cardiol. 2016;67:2224–34.

Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, et al. Prediction of thrombotic and bleeding events after percutaneous coronary intervention: CREDO-Kyoto thrombotic and bleeding risk scores. J Am Heart Assoc. 2018;7:e008708.

Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, et al. Thrombolysis in myocardial infarction (TIMI) trial-Phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 1988;11:1–11.

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation. 2011;123:2736–47.

The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–82.

Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.

Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation. 2009;119:987–95.

Kimura T, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Iwabuchi M, et al. Long-term safety and efficacy of sirolimus-eluting stents versus bare-metal stents in real world clinical practice in Japan. Cardiovasc Interv Ther. 2011;26:234–45.

Sianos G, Morel M-A, Kappetein AP, Morice M-C, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219–27.

CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–39.

Capodanno D, Mehran R, Valgimigli M, Baber U, Windecker S, Vranckx P, et al. Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. Nat Rev Cardiol. 2018;15:480–96.

Généreux P, Giustino G, Witzenbichler B, Weisz G, Stuckey TD, Rinaldi MJ, et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol. 2015;66:1036–45.

Valgimigli M, Costa F, Lokhnygina Y, Clare RM, Wallentin L, Moliterno DJ, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J. 2017;38:804–10.

Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, et al. High-dose versus low-dose pitavastatin in Japanese patients with stable coronary artery disease (REAL-CAD). Circulation. 2018;137:1997–2009.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart J-C, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35.

Onuma Y, Kimura T, Räber L, Magro M, Girasis C, Van Domburg R, et al. Differences in coronary risk factors, procedural characteristics, mortality and stent thrombosis between two all-comers percutaneous coronary intervention registries from Europe and Japan: a patient-level data analysis of the Bern-Rotterdam and j-Cypher. EuroIntervention. 2015;11:533–40.

Thông tin
Thông tin xuất bản

Cardiovascular Intervention and Therapeutics

Thông tin tác giả